𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mo1647 Inhibition of EZH2/EZH1 by UNC1999 Enhances the Potency of the EGFR Inhibitor Gefitinib in Colon Cancer Cells

✍ Scribed by Katona, Bryson; Liu, Yuanyuan; Ma, Anqi; Jin, Jian; Hua, Xianxin

Book ID
122117292
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
54 KB
Volume
146
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Curcumin enhances the effects of 5-fluor
Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R
✍ Bhaumik B. Patel; Radha Sengupta; Sadia Qazi; Hetal Vachhani; Yingjie Yu; Arun K πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 French βš– 297 KB πŸ‘ 1 views

## Abstract Curcumin (diferuloylmethane), which has been shown to inhibit growth of transformed cells, has no discernible toxicity and achieves high levels in colonic mucosa. 5‐fluorouracil (5‐FU) or 5‐FU plus oxaliplatin (FOLFOX) remains the backbone of colorectal cancer chemotherapeutics, but wit

Inhibition of proliferation and inductio
Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (β€˜Iressa’) is independent of EGFR expression level
✍ Manuela Campiglio; Alberta Locatelli; Clelia Olgiati; Nicola Normanno; Giulia So πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 297 KB πŸ‘ 2 views

High expression of the epidermal growth factor receptor (EGFR) in breast carcinoma confers a growth advantage to the tumor cells. The EGFR tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') has clinical activity in a wide range of tumor types, although the mechanism(s) by which it exerts its ant